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Abstract ‘Primary sinonasal tract and nasopharyngeal
adenoid cystic carcinomas (STACC) are uncommon
tumors that are frequently misclassified, resulting in inap-
propriate clinical management. Eighty-six cases of STACC
included 45 females and 41 males, aged 12–91 years (mean
54.4 years). Patients presented most frequently with
obstructive symptoms (n = 54), followed by epistaxis
(n = 23), auditory symptoms (n = 12), nerve symptoms
(n = 11), nasal discharge (n = 11), and/or visual symp-
toms (n = 10), present for a mean of 18.2 months. The
tumors involved the nasal cavity alone (n = 25), naso-
pharynx alone (n = 13), maxillary sinus alone (n = 4), or
a combination of the nasal cavity and paranasal sinuses
(n = 44), with a mean size of 3.7 cm. Patients presented
equally between low and high stage disease: stage I and II
(n = 42) or stage III and IV (n = 44) disease. Histologi-
cally, the tumors were invasive (bone: n = 66; neural:
n = 47; lymphovascular: n = 33), composed of a variety
of growth patterns, including cribriform (n = 33), tubular
(n = 16), and solid (n = 9), although frequently a com-
bination of these patterns was seen within a single tumor.
Pleomorphism was mild with an intermediate N:C ratio in
cells containing hyperchromatic nuclei. Reduplicated
basement membrane and glycosaminoglycan material was
commonly seen. Necrosis (n = 16) and atypical mitotic
figures (n = 11) were infrequently present. Pleomorphic
adenoma was present in 9 cases; de-differentiation was
seen in two patients. Immunohistochemical studies showed
positive reactions for pan-cytokeratin, CK7, CK5/6,
CAM5.2, and EMA, with myoepithelial reactivity with
SMA, p63, calponin, S100 protein and SMMHC. CD117,
CEA, GFAP and p16 were variably present. CK20 and HR
HPV were negative. STACC needs to be considered in the
differential diagnosis of most sinonasal malignancies,
particularly poorly differentiated carcinoma, olfactory
neuroblastoma and pleomorphic adenoma. Surgery
(n = 82), often accompanied by radiation therapy
(n = 36), was generally employed. A majority of patients
developed a recurrence (n = 52) 2–144 months after initial
presentation. Overall mean follow-up was 19.4 years
(range 0.4–37.5 years): 46 patients died with disease (mean
6.4 years); 5 were alive with disease (mean 5.4 years), and
35 patients were either alive or had died of unrelated causes
(mean 16.3 years). ACC of the SNT is uncommon.
Recurrences are common. The following parameters, when
present, suggest an increased incidence of either recurrence
or dying with disease: mixed site of involvement, high
stage disease (stage IV), skull base involvement, tumor
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recurrence, a solid histology, perineural invasion, bone
invasion, and lymphovascular invasion.
Keywords Adenoid cystic carcinoma  Paranasal
sinuses  Nasal cavity  Staging  Prognosis 
Histology  Immunohistochemistry
Introduction
Adenocarcinoma of the sinonasal tract (SNT) is separated
into salivary gland-type adenocarcinoma and non-salivary
gland-type adenocarcinoma [1–4]. Adenocarcinomas of
sinonasal tract can originate from the respiratory epithe-
lium or the underlying mucoserous glands, with most
(especially salivary gland type) arising from the mucose-
rous glands [5]. Malignant sinonasal tract neoplasms are
relatively uncommon, accounting for between 2 and 3 % of
all upper aerodigestive tract malignancies [6]. Squamous
cell carcinoma is the most common sinonasal tract cancer,
but adenoid cystic carcinoma (ACC) is the second most
common malignancy and the most common salivary gland-
type tumor of the sinonasal tract (nasal cavity, paranasal
sinuses, and nasopharynx, hereinafter referred to collec-
tively as the sinonasal tract, i.e. STACC) [7]. ACCs com-
prise between 10 and 15 % of all malignant salivary gland
tumors. A review of the English literature (1966–2012)
reveals over 2,100 cases of STACC, representing approx-
imately 10–18 % of all malignant sinonasal tract neo-
plasms, and representing approximately 13 % of all ACC
of the head and neck (Table 1) [5–119]. STACC is thought
to arise from the minor mucoserous glands which lie within
the mucosa, below the respiratory-type epithelium of the
nasal cavity and paranasal sinuses, although surface deri-
vation has also been postulated [1, 5]. The high frequency
of misdiagnosis of this tumor when it arises in the sinonasal
tract results in inappropriate therapy and therefore reduced
patient outcome. The English literature contains many case
reports, small series, and a few larger series, all of which
focus on a particular feature. Specifically, the series often
present all salivary gland tumor types together [39, 40, 57,
67, 89, 91, 97, 99, 106, 120–127], encompass all head and
head anatomic sites, describe adenoid cystic carcinoma
only but in all sites [5, 6, 12, 17, 22, 31, 32, 35, 39, 47, 50,
52, 57, 59, 66, 73, 75, 76, 87, 91–93, 98, 100, 101, 106,
112, 113, 117, 128–130], or only one subsite but all tumors
combined. Many small series focus on the radiographic
findings alone [36, 62, 88, 96, 99, 108–110, 112, 117, 131–
134], or specifically address a particular therapy (radiation)
[8, 20, 24, 25, 33, 54, 63, 66, 69, 86, 92, 95, 111] for all
tumor types of a particular anatomic site. It is the intention
of this study to provide a comprehensive analysis of
STACC incorporating the use of clinical features,
histologic findings, immunohistochemical results, therapies
employed, and patient follow-up applied to a group of 86
patients with this tumor, generating statistically significant
findings.
Methods
One hundred and seven cases of primary sinonasal tract
adenoid cystic carcinomas were selected involving the
nasal cavity, paranasal sinuses (sphenoid, maxillary, eth-
moid, and frontal sinuses) and nasopharynx. The cases
were retrieved from the files of the Otorhinolaryngic-Head
& Neck Tumor Registry of the Armed Forces Institute of
Pathology (AFIP), Washington, DC, between 1970 and
1998 and from the consultation files (2003–2011) of one of
the authors (LDRT). However, 21 patients were excluded
from further consideration because of at least one of the
following reasons: (1) Paraffin blocks were unavailable for
additional sections or immunophenotypic analysis; (2) The
original submitted case did not have sufficient demo-
graphic information supplied from which to obtain ade-
quate follow-up information; and (3) Immunophenotypic
analysis confirmed a diagnosis of lymphoma or olfactory
neuroblastoma. The cases which were reclassified were all
before 1985, and had all been signed out as ‘‘poorly dif-
ferentiated malignant neoplasm,’’ ‘‘consistent with,’’
‘‘suggestive of,’’ or ‘‘suspicious for’’ adenoid cystic carci-
noma and had not benefited from electron microscopy or
immunophenotyping at the time of the original diagnosis.
Therefore, the remaining 86 patients compose the subject
of this study, chosen from a review of 22,111 (0.33 %)
benign or malignant primary sinonasal tract neoplasms
seen in consultation during this time. Seventy-one cases
were obtained from civilian sources, including university
medical centers and foreign contributors, 12 cases from
military hospitals, and 3 cases from Veterans Administra-
tion Medical Centers. A cohort of these cases was previ-
ously reported with a focus on adenoid cystic carcinoma ex
pleomorphic adenoma [105], without any of the remaining
cases included in other reports.
Materials within the files were supplemented by a
review of the patient demographics (gender, age, race) and
symptoms at presentation (epistaxis, headache, facial
numbness, nerve dysfunction, nasal obstruction, nasal
mass, polyps, sinusitis, discharge, difficulty breathing,
blurring of vision, pain, hearing changes, otalgia, tinnitus)
including duration. In addition, we reviewed the medical
history (specifically noting any mention of major salivary
gland primary), imaging, surgical pathology and operative
reports, and obtained follow-up information by direct
written or oral communication with the referring patholo-
gist, patient’s physician, oncology data services and tumor
Head and Neck Pathol (2014) 8:88–109 89
123
registries, or the patient (patient’s family member[s]).
Follow-up data, available for all patients, included infor-
mation regarding the exact tumor location, the specific
treatment modalities used, the presence or absence of
recurrent or metastatic disease, and the current status of the
disease and patient. The series covers over four decades,
with several changes in the staging criteria. This series
includes primary tumors from the sinonasal tract, which
includes the following sites and subsites: nasal cavity
(floor, septum, lateral wall, roof and vestibule); maxillary
sinus (floor, anteriolateral, medial and posterior walls,
roof); ethmoid sinus, frontal sinus, sphenoid sinus and
nasopharynx. The staging system takes into consideration
the epicenter of the tumor in these sites and subsites at the
time of diagnosis and places them in the context of
extension into bone and neighboring sites and structures,
including the oral cavity, soft tissues of the cheek and nose,
pterygomaxillary fossa, orbit, pituitary, and skull base
(including intracranial extension) (Fig. 1) [17, 135]. These
determinations were drawn from an analysis of the clinical,
imaging and/or operative data. Preoperative imaging
studies were available in 47 cases, including computed
tomography and magnetic resonance imaging studies.
These studies give complementary information about size,
exact site of origin and extension into adjacent structures
and extent of the tumor. Reports were reviewed in all these
cases, with personal review of 31 patients’ images. It is
important for the radiologist to carefully assess nerve
involvement, especially along the branches of the trigem-
inal nerve, in order to evaluate possible intracranial
extension. Axiomatic, perineural invasion is not unique to
adenoid cystic carcinoma [131]. All patients were staged
by the authors as part of this report according to the 2010
American Joint Commission on Cancer Staging [136].
Since most samples were submitted in a fragmented
fashion, definitive margins were not assessed. Margins
were frequently not identified by the surgeons. Further-
more, as we did not prosect the cases and most were sub-
mitted as consultations, assessment of margin status is
unreliable. Patients who were found to have a contiguous
non-sinonasal site primary ACC (palate, alveolar ridge,
orbit) were excluded from further consideration, as were
any patients who had a major salivary gland (parotid spe-
cifically) primary tumor. No patients in this series were
part of a syndrome associated kindred (no familial cancer
syndrome). It is important to add that as a tertiary pathol-
ogy review center, conducting a retrospective review of
these patients, we did not treat the patients. This clinical
investigation was conducted in accordance and compliance
with all statutes, directives, and guidelines of an Internal
Review Board authorization (#5968) performed under the
direction of Southern California Permanente Medical
Group and the Code of Federal Regulations, Title 45, Part
46, and the Department of Defense Directive 3216.2
relating to human subjects in research.
Hematoxylin and eosin-stained slides from all 86 cases
were reviewed, with a range of 1–37 slides reviewed per














Nasal cavity alone 87
Nasopharynx alone 90
Maxillary sinus alone 433
Other single sinus 75




a Results are incomplete, as value was not always stated
Fig. 1 A diagrammatic representation of tumor stage, based on a
maxillary sinus primary tumor (AJCC 2010). T1: confined to the sinus
with no bone destruction; T2: tumor causing bone erosion into hard
palate; T3: tumor invades into the subcutaneous tissues (and middle
nasal meatus); T4: tumor invades into anterior orbital content
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case (mean 4.7 slides), with each slide often containing
multiple different sections. The following specific macro-
scopic and histologic observations were recorded for each
tumor: exact tumor location; lateralization; tumor size
(greatest dimension in centimeters); surface epithelium
(present or absent); surface origin or involvement (Fig. 2);
surface ulceration; tumor extension (bone, soft tissue,
minor gland, neural or lymphovascular invasion; Fig. 3);
architectural patterns of growth [tubular, trabecular, glan-
dular, cribriform, solid, anastomosing cords, cystic spaces,
epithelial-myoepithelial carcinoma-like, pleomorphic ade-
noma (Fig. 4)]; glycosaminoglycan matrix material
(Fig. 5); reduplicated basement membrane; necrosis
(present or absent); sclerosis; hemorrhage; calcification;
nuclear pleomorphism (mild, moderate, severe: Fig. 6);
presence of nucleoli; nuclear to cytoplasmic ratio; mitotic
figures (number of mitotic figures per 10 high power fields
[magnification at 940 with a 910 objective lens using an
Olympus BX41 microscope]); atypical mitotic figures
(present or absent, and defined by abnormal chromosome
spread, tripolar or quadripolar forms, circular forms, or
indescribably bizarre); and the presence of other micro-
scopic pathologic findings. Neural invasion was defined as
invasion of neoplastic cells into the perineural space (per-
ineural) or between nerve fascicles (intraneural), irrespec-
tive of the size of the nerve (nerve diameter of B1 mm
or [1 mm) and whether the nerve was within the tumor
or B1 cm of the tumor mass [38]. No meaningful separation
was achieved by separating perineural from intraneural
invasion, and so these groups were combined in this evalu-
ation. Lymphovascular invasion required the presence of
neoplastic cells within an endothelial lined space, with or
without thrombus and whether free floating or attached to the
endothelium. Stromal-epithelail retraction was carefully
excluded, seeking endothelial cells before definitive lym-
phovascular invasion was noted, but without performing
immunohistochemistry for a vascular marker. The tumors
were misclassified by the contributor in 54.6 % (n = 47),
with pleomorphic adenoma, squamous cell carcinoma, basal
cell adenoma, monomorphic adenoma, basaloid squamous
cell carcinoma, epithelial-myoepithelial carcinoma, inverted
papilloma, and carcinoma, not otherwise specified, diag-
nosed most commonly.
Immunophenotypic analysis was performed in all cases
with sufficient suitable material by a standardized Envi-
sionTM method employing 4 lm-thick, formalin fixed,
paraffin embedded sections on a single representative
block. Table 2 documents the pertinent, commercially
available immunohistochemical antibody panel used. Epi-
tope retrieval was performed, as required by the manu-
facturer guidelines. Standard positive controls were used
throughout, with serum used as the negative control. The
antibody reactions were catalogued by location and graded
as absent to weak (0–1?), moderate (2?–3?) and strong
(4?) staining, and the fraction of positive cells was
determined by separating them into four groups: \10 %
(focal), 11–50 %, 51–90 %, and [90 % (diffuse); prolif-
eration marker and p53 were separated into \2 %, 2–10,
[10 %.
To verify acceptable MYB translocation status and
expression as well as human papillomavirus (HPV) status,
a small tissue microarray was constructed using two 1 mm
cores from 12 random cases with available material. FISH
for MYB was performed as follows: Nick translated probes
produced from bacterial artificial chromosome (BAC)
clones were obtained from Empire Genomics as a hybrid-
ization-mixture with human cot-1 DNA. Tissue microarray
slides were incubated at 56 C overnight, deparaffinized
using xylene, and rehydrated using a graded series of eth-
anol baths. Slides were heated in target retrieval solution
(Dako) at 95 C for 40 min, rinsed with distilled water for
5 min, digested with Proteinase K at room temperature for
8 min, rinsed with distilled water for 5 min, then dehy-
drated with a graded series of alcohol baths. BAC clone
RP11-104D9 labeled with 5-Fluorescein and BAC clone
RP11-170P19 labeled with 5-carboxy-X-rhodamine (5-
Rox) were used. The probe/in situ hybridization buffer
mixture was distributed across the microarray area, covered
with a glass cover slip, and sealed with rubber cement.
Slides were incubated in a humidified chamber at 73 C for
5 min to denature the microarray DNA followed by 37 C
for 18 h to hybridize with the probes. After hybridization,
slides were washed with 2X SSC at room temperature for
5 min, 0.4X SSC/0.3 % NP-40 at 73 C for 2 min, 2X
SSC/0.1 % NP-40 at room temperature for 1 min, and
rinsed with distilled water at room temperature for 1 min.
Fig. 2 An intact surface mucosa overlying the cribriform and cystic
patterns of a sinonasal adenoid cystic carcinoma
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Slides were counterstained using DAPI in Vectashield
mounting medium (Vector Laboratories), covered with a
glass cover slip, and sealed with CytoSeal XYL. Slides
were examined on a fluorescence microscope (Imager A.2,
Carl Zeiss Imaging Solutions GmbH) equipped with a
1509 Plan-APOCHROMA objective and images captured
using a digital camera (AxioCam MRm, Zeiss) controlled
by AxioVision software (Release 4.8, Zeiss). A minimum
of 100 nuclei were examined per specimen to obtain the
consensus probe count. MYB immunohistochemistry was
performed as follows: Tissue sections were cut and incu-
bated with anti-MYB rabbit monoclonal antibody (clone
EP769Y;1:200 dilution; Epitomics Inc., Burlingame, CA,
USA) using a DAKO (Carpinteria, CA, USA) autostainer
after antigen retrieval for 30 min. The antibody recognizes
a synthetic peptide corresponding to residues near the
N-terminus of human MYB. The avidin-biotinimmunoper-
oxidase technique was used. Diaminobenzidine was the
chromogen, and sections were counterstained with hema-
toxylin. MYB immunostaining was considered positive if
greater than 5 % of tumor cells displayed strong nuclear
immunoreactivity. In situ hybridization for high-risk HPV
was performed using an automated benchmark XT system
(Ventana Medical Systems, Inc., Tucson, AZ). The
INFORM HPV III family 16 probe cocktail, with affinity
for high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, and 66), was applied and the reaction was
developed using a Hybrid Ready Detection Kit (Ventana
Medical Systems, Inc., Tucson, AZ). Positive signals
included punctate or diffuse reactivity within tumor nuclei.
A review of publications in English (MEDLINE
1966–2012) was performed, with all cases reported with
clinical, histologic, immunophenotypic and/or follow-up
information on STACC evaluated and included in the
review, but excluding ‘‘Quiz’’ or ‘‘Case of the Month’’ type
reports. Many cases were excluded if the lesion arose pri-
marily in the oral cavity, upper lip or oropharynx or repre-
sented a different tumor type, or if the information was too
generalized and non-specific to make a meaningful inter-
pretation of the demographics, histologic features, immu-
nohistochemistry findings, or patient outcome.
Statistical evaluation was performed using a standard
statistics software package with categorical variables ana-
lyzed using Chi square tests and Fisher’s Exact tests to
compare observed and expected frequency distributions.
Comparison of means between groups was made with
unpaired t tests or one-way analysis of variance, depending
on whether there were two groups or more than two groups,
respectively. Multiple comparisons were analyzed using
the Tukey method and log-rank analysis. Linear regression
was used to investigate two measured variables, and
Pearson correlation coefficients were generated to measure
the strength of the association. Survival curves were gen-
erated using the Kaplan–Meier product-limit method.
Confidence intervals of 95 % were generated for all posi-
tive findings. The alpha level was set at p \ 0.05.
Fig. 3 Bone invasion (left) and
perineural and intraneural
invasion (right)




The patients included 45 women and 41 men (Table 3) who
ranged in age from 12 to 91 years, with a mean age at pre-
sentation of 54.4 years (median, 58 years; mode, 60 years).
There was no statistical difference in mean age at presentation
between the genders (p = 0.401). There was no significant
difference in overall survival between the genders
(p = 0.687). Of note, there was no significant decrease in
overall survival for patients who were C60 years of age at
initial presentation than those who were younger (p = 0.470).
The patients presented clinically with a variety of
symptoms referable to the tumor location where obstruc-
tive symptoms (including mass, polyps, cheek swelling;
n = 54) and epistaxis (frequent and profuse; n = 23)
accounted for the most frequent presenting symptoms.
Patients experienced epistaxis for a mean of 13.1 months, a
finding which was not statistically significantly related to
survival (p = 0.200). Patients frequently reported more
than one symptom, including auditory symptoms (changes
in hearing, otitis, otalgia tinnitus; n = 12), nerve symptoms
(numbness, nerve dysfunction, paresthesia, epiphora,
paralysis, anosmia, trismus, pain; n = 11), nasal discharge,
allergies, rhinitis or sinusitis (n = 11), visual symptoms
(blurred vision, exophthalmos, proptosis, ptosis, diplopia,
decreased vision; n = 10), headache (n = 7), or a neck
mass (n = 1) or combination thereof.
The duration of symptoms ranged from a couple of
weeks to 120 months, with an average of 18.2 months.
There was no statistical difference in average length of
symptoms between the genders (p = 0.065). We were




The tumors occurred in the nasal cavity only (n = 25),
nasopharynx only (n = 13), maxillary sinus only (n = 4),
or in a mixed site (n = 44; nasal cavity, paranasal sinuses,
including ethmoid, frontal, sphenoid, and/or nasopharynx)
(Table 3; Fig. 1), determined by a combination of imaging
studies, intraoperative determination, and gross resection
specimen evaluation. Lesions described as ‘‘nasal cavity
alone’’ or ‘‘nasal cavity and paranasal sinuses’’ may have
had tumors which involved a specific subsite (septum,
turbinate) but were not designated as such. None of the
tumors in this series involved the oral cavity, lateral orbit
(lacrimal gland), or cribriform plate at initial presentation.
Fig. 4 a Low power of a sinonasal adenoid cystic carcinoma
showing various patterns of growth. Palisaded neoplastic cells around
areas of glycosaminoglycan material. Hyperchromasia of the nuclei is
appreciated. b A solid pattern demonstrated focal clefting around the
periphery of the nodules of tumor. The cells had a very high nuclear
to cytoplasmic ratio, with heavy nuclear chromatin distribution. c The
large cystic spaces were filled with light pink to heavily ‘‘blue’’
stained material. There is an intact surface respiratory epithelium
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The tumors ranged in size from 1 to 11 cm, with a mean of
3.7 cm (median, 3.2 cm). There was no statistically sig-
nificant difference in the size of tumors between the gen-
ders (women, 3.9 cm; men, 3.5 cm; p = 0.299). There was
a statistical difference in the mean size of tumors which
involved certain sites (p = 0.0001), such as nasopharynx
alone (mean 2.7 cm), nasal cavity alone (mean 3.0 cm)
versus mixed sites (mean 4.4 cm). However, size alone,
using both a continuous variable and selected cut-off points
(4 cm is shown), did not correlate to a worse patient
outcome as an independent parameter, even when carci-
noma ex-pleomorphic adenoma cases were excluded (car-
cinoma ex-pleomorphic adenoma: mean = 3.3 cm; all
remaining cases: mean = 3.7 cm) (p = 0.751). The
majority of lesions were received as multiple, irregular
fragments of soft tissue, especially in the biopsy and wide
excision specimens. The cut surface, when not submitted in
multiple fragments, was composed of grayish pink to tan
firm soft tissue.
Microscopic
The majority of tumors demonstrated, for the most part,
overlying respiratory or metaplastic squamous surface
epithelium (n = 65) (Figs. 2, 4c; Table 4), with varying
degrees of ulceration in most of these cases. Surface
involvement and/or derivation of the neoplasm was noted
in 12 tumors, although invasion into versus from the sur-
face epithelium was often difficult to accurately determine.
Tumor cell invasion into adjacent bone (Fig. 3) was noted
in the vast majority of cases (n = 66), and was statistically
associated with a worse patient outcome (p = 0.0005).
Neural invasion (Fig. 3) was detected in 47 patients. The
presence of neural invasion was statistically associated
with an adverse patient outcome (p \ 0.0001). Lympho-
vascular invasion was identified in 33 tumors, a finding
also associated with a worse patient outcome (p = 0.0058).
Single cell infiltration was detected in only a few cases
(n = 8).
Fig. 5 ‘‘Blue-goo’’ matrix
material could appear
eosinophilic and granular (left)
while the more
characteristically ‘‘blue’’
mucinous material (right) was
most common. ‘‘Carrot-shaped’’
nuclei surround the cysts
Fig. 6 A high power illustrating the bland nuclear appearance and an
intermediate to high nuclear to cytoplasmic ratio. Note the small
gland or tubule formation, in addition to the larger cysts
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A variable architectural appearance was characteristic
both between tumors as well as within tumors, but a spe-
cific architectural pattern tended to predominate in each
case: cribriform (n = 33; Figs. 2, 4a), tubular (n = 16;
Figs. 2, 4a), and solid (n = 9; Fig. 4b), while anastomo-
sing cords or widely dilated cystic spaces (Fig. 4c) were
noted more sporadically. In 28 tumors, a 70 % dominant
pattern was not detected, and so a specific architectural
pattern was not assigned. Tumor cells focally demonstrated
a bilayered epithelial-myoepithelial carcinoma-like distri-
bution (n = 4), while two carcinomas had areas of de-
differentiation. Nine cases contained benign residual
pleomorphic adenoma, in which ACC represented the
malignant component of a carcinoma ex-pleomorphic
adenoma (see previously reported case series by Toluie
et al. [105]). The characteristic glycosaminoglycan matrix
material (Fig. 5) was identified in most cases (n = 49),
although prominent in 13 cases. This material often created
the ‘‘rotary telephone dial’’ appearance. Reduplicated
basement membrane material was also noted in most cases,
often creating a jigsaw puzzle-like appearance. Rare cal-
cifications were noted. The nuclei displayed a ‘‘carrot’’,
‘‘angular’’ or ‘‘peg’’ shape as they palisaded around the
periphery of the tumor nests, showing only mild to mod-
erate nuclear pleomorphism (Fig. 6). Palisading was often
inconspicuous, and so could not be solely relied upon for
the diagnosis of ACC. Nucleoli were frequently present,
although they were usually small. Irregular, prominent,
macronucleoli were only noted rarely. Most cells had a
moderate or intermediate nuclear to cytoplasmic ratio,
although a high N:C ratio could be found. Mitoses were
seen in most cases (n = 71), with a range of 0–109 and a
mean of 7.3 mitoses per 10 high power fields (see Materials
and Methods). Atypical mitotic figures were only infre-
quently present (n = 11), and when present were not
associated with a worse clinical outcome (p = 0.35).
Tumor necrosis, whether apoptosis or comedo-type
necrosis (n = 16) was not associated with a worse patient
outcome (p = 0.806). Peritumoral fibrosis and inflamma-
tion were seen, but were not a dominant feature in any
tumor. Intratumoral fibrosis or sclerosis was uncommon
(n = 16), but was seen in most of the cases that also
contained pleomorphic adenoma. Using standard grading
criteria, [137, 138] there were 22, 37 and 27 Grade 1, 2,
and 3 tumors, respectively. The 28 tumors which lacked a
dominant histologic pattern, were separated based on other
grading criteria.
Immunohistochemical Results
All lesions tested reacted with a pan-cytokeratin and CK5/6
(Table 5), the latter sometimes differentially expressed,





Cytokeratin-pan (AE1/AE3:M3515) mm Dako, Carpinteria, CA 1:40 CC1, 30 min
CK5/6 (D5/16 B4) mm Dako 1:25 E2, 20 min
CK7 (OV-TL-12/30) mm Dako 1:200 CC1, 30 min
Epithelial membrane antigen (EMA) (E29) mm Ventana Medical Systems, Tucson, AZ Neat CC1, 30 min
CK20 (KS20.8) mm Ventana Neat CC1, 30 min
CEA(p) rp Lab Vision, NeoMarkers, Fremont, CA 1:250 CC1, 30 min
CD117 (C-Kit) rp Dako 1:400 CC1, 30 min
S-100 protein rp Dako 1:2000 CC1, 30 min
Calponin mm Abcam, Cambridge, England Neat CC1, 30 min
p63 (7jul) mm Leica Microsystems, Buffalo Grove, IL 1:40 E2, 30 min
Smooth muscle actin (asm-1) mm Leica Microsystems 1:200 E2, 20 min
Muscle specific actin (HHF35) mm Enzo Life Sciences, Farmingdale, NY 1:100 CC1, 30 min
Smooth muscle myosin heavy chain (SMMS-1) mm Dako 1:100 CC1, 30 min
Glial fibrillary acidic protein (GFAP)(6F2) mm Dako 1:200 CC1, 30 min
p16INK4a (E6H4) mm MTM Laboratories (Ventana Medical Systems) Neat CC1, 30 min
p53 (DO-7) mm Dako Neat CC1, 30 min
Ki67 (MIB1) mm Dako 1:100 CC1, 30 min
MYB (EP769Y) mm Epitomics, Inc, Burlingame, CA 1:200 CC1, 30 min
mm Mouse monoclonal, rp rabbit polyclonal
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highlighting the luminal or tubular epithelium. A variety of
epithelial markers were tested in this clinical series with
CK7 and EMA identified most frequently. CK20 was
absent in all cases. The myoepithelial and/or basal zone
areas were variably reactive with S100 protein, calponin,
smooth muscle actin, and p63 (Fig. 7), while muscle spe-
cific actin and glial fibrillary acidic protein was weakly and
focally reactive in a few cases (Table 4). CD117 accentu-
ated the epithelial cells, but tended to be found in areas in
which a tubular histology predominated (Fig. 7). The
proliferation marker (Ki-67) reacted with up to 22 % of the
nuclei, but most cases showed reaction in \10 %, with an
overall lack of a high proliferation index. p53 was identi-
fied in the nuclei of 22 cases, but it was only increased
([10 %) in nine cases. Both of these markers suggest an
overall low tumor turnover. p16 was identified in all tested
cases (100 %), yielding both a nuclear and cytoplasmic
reaction, stronger in the luminal cells, although all cases
were negative for high-risk HPV. p16 was noted in both the
pleomorphic adenoma and ACC areas, although with a
greater intensity in the cytoplasm of the malignant areas,
and a stronger nuclear expression in the PA areas.
Of the 12 cases analyzed for MYB translocation using
FISH, eight had interpretable results. Of these, five (63 %)
showed results consistent with translocation. One of three
cases (33 %) negative for the translocation showed positive
staining for MYB by immunohistochemistry, whereas 4 of 5
cases with the translocation showed staining. Of cases with
non-interpretable FISH results, 2 of 3 showed staining, and
one had non-interpretable results.
Treatment and Follow-up
The vast majority of patients were treated by partial or
complete surgical excision (n = 82); however, complete
extrication of the tumor was not likely due to the complex
anatomy of the region. Forty-six patients were treated by
surgical resection only without any additional therapy




Females 45 (52 %)




Women (mean) (p = 0.401) 52.9
Men (mean) 56.2
Maxillary sinus only (mean) (p = 0.006) 48.0
Nasal cavity only (mean) 66.0
Nasopharynx (mean) 45.0
Mixed locations (mean) 58.0
Stage I (mean) (p = 0.725) 52.0
Stage II (mean) 60.0
Stage III (mean) 56.0




Duration (mean; women) (p = 0.065) 22.5
Duration (mean; men) 13.2
Obstructive symptoms (including mass, polyps) 54
Epistaxis (mean duration: 13.1 mo) (p = 0.200) 23
Auditory symptoms (hearing changes, otitis, otalgia,
tinnitus)
12
Nerve symptoms (numbness, nerve dysfunction,
paralysis, pain)
11
Nasal discharge, allergies, sinusitis 11




Nasal cavity alone 25 (29 %)
Nasopharynx alone 13 (15 %)
Maxillary sinus alone 4 (5 %)
Mixed location (more than one topographic site) 44 (51 %)




Female (mean) (p = 0.299) 3.9
Male (mean) 3.5
In patients with epistaxis (mean) (p = 0.212) 3.5
Nasopharynx alone (mean) 2.7
Single anatomic site (mean) (p = 0.0001) 3.0
Mixed anatomic sites (mean) 4.4
Carcinoma ex-pleomorphic adenoma 3.3








I 37 (43 %)
II 5 (6 %)
III 15 (17 %)
IV 29 (34 %)
* More than one symptom may have been experienced by the patients
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(mean follow-up, 12.2 years): 27 died with disease (mean
6.9 years), 9 had died without evidence of disease (mean
14.1 years), and 10 are alive without evidence of disease at
last follow-up (mean 24.9 years). Within this group man-
aged by surgery alone, 30 patients (65 %) developed
recurrent disease, and 10 (22 %) developed metastatic
disease (lung, bone, liver, brain and skin). Of the patients
who developed recurrent disease (managed further by
surgery [n = 25] or radiation therapy [n = 5] or a com-
bination with chemotherapy [n = 4]), 25 died with disease
(mean 6.7 years), 3 had died without evidence of disease
(mean 20.1 years), and 2 are alive without evidence of
disease at last follow-up (mean 19.3 years). All 10 patients
who developed metastatic disease were dead of their dis-
ease (mean 7.4 years). Eight of the 10 patients who had
metastatic disease had also developed locally recurrent
disease.
An additional 36 patients were managed by an initial
combination of surgery and radiation (mean follow-up,
8.8 years): 18 died with disease (mean 5.7 years), 5 had died
without evidence of disease (mean 15.4 years), 4 are alive
with disease (mean 6.4 years), and 9 are alive without evi-
dence of disease at last follow-up (mean 12.2 years). Within
this group managed initially by a combination of surgery and
radiation, 22 patients (61 %) developed recurrent disease,
and 11 (31 %) developed metastatic disease. Of the patients
who developed recurrent disease (managed further by sur-
gery [n = 20] or a combination with radiation and/or che-
motherapy [n = 2]), 16 died with disease (mean 6.1 years),
4 are alive with evidence of disease (mean 6.4 years), 2 had
died without evidence of disease (18.0 years). Nine of the 11
patients who developed metastatic disease had died of their
disease (mean 6.3 years), while 2 patients are alive with
disease at last follow-up (mean 8.3 years). Eight of the
patients who had metastatic disease had also developed
locally recurrent disease.
Four patients were managed with radiation therapy only:
2 patients died without recurrence or metastatic disease
(mean 4.1 years), one was alive with disease (1.5 years),
and one died with locally recurrent disease at 6.7 years.
While the overall survival for STACC was grim (53.4 %
died with disease, mean of 6.5 years, Fig. 8), a number of
patients were alive or had died without evidence of disease
at last follow-up (35 patients; 39.5 %; Table 6). Overall, 35
patients were alive or had died without evidence of disease
at last contact (mean 16.3 years), while 51 patients were
either alive or had died with evidence of disease (mean
6.3 years; Table 6). While a separation was made between
patients who had local disease only (n = 18) and those
who had disseminated disease (n = 33), there was no sta-
tistical difference in overall mean years of survival (mean




Possible surface epithelial involvement 12
No surface derivation 74
Neural invasion (p \ 0.0001) 47
Bone invasion (p = 0.0005) 66
Lymphovascular invasion (p = 0.0058) 33
Individual, single cell invasion 8
Growth pattern
Cribriform (C70 %) 33
Tubular (C70 %) 16




Severe (de-differentiation) (p = 0.105) 2









Mean (per 10 HPF) 7.3
Range 0–109
Atypical figures (present) 11
Other features
Anastomosing cords 17
Large cystic spaces 13








Unknown or positive 72





HPF high power field
p Values are included to indicate features associated with a poor
patient outcome when present
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6.4 vs. 6.3 years, respectively; p = 0.27). When the
patients died with or from their disease (the distinction is
often difficult to ascertain retrospectively), they in general
died a mean of 6.4 years after initial presentation
(Table 6). Twenty-four patients survived for more than
5 years with their tumors before dying of their disease up
Table 5 Immunohistochemical
panel results
Antigen/antibody Number of cases with
positive reactions
Predominant pattern of reactivity
Pancytokeratin 42/42 (100 %) Diffuse, luminal and tubular
CK5/6 42/42 (100 %) Diffuse, luminal and tubular
CK7 42/42 (100 %) Diffuse, luminal and tubular
Epithelial membrane antigen 40/42 (95 %) Focal, luminal and tubular
CK20 0/42 (0 %) Absent
CEA(p) 28/42 (67 %) Focal, mostly tubular
CD117 38/42 (90 %) Weak to diffuse, luminal
S100 protein 32/42 (76 %) Diffuse, nuclear and cytoplasmic
Calponin 25/30 (83 %) Basal layer
p63 35/42 (83 %) Diffuse, basal layer
Smooth muscle actin 42/42 (100 %) Focal to diffuse, abluminal/basal
Muscle specific actin 10/42 (24 %) Focal, abluminal/basal
Smooth muscle myosin heavy chain 9/13 (69 %) Focal to diffuse, abluminal/basal
Glial fibrillary acidic protein 4/42 (10 %) Focal only
p16 13/13 (100 %) Focal to diffuse, luminal (nuclear
and cytoplasmic)
p53 31/42 (74 %) 2–80 % of nuclei positive
Ki67 32/42 (76 %) 1–22 % of nuclei positive
MYB 6/11 (55 %) 5/8 broken by FISH; 4/5 positive
for MYB by IHC
HR HPV 0/13 (0 %) Negative
Fig. 7 Immunohistochemistry
was not requisite for the
diagnosis. However, the
following patterns were present:
CD117 (C-kit) was often
accentuated around true lumens
(left), while the p63 highlighted
the basal/myoepithelial cells
within the tumor (right)
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to 17 years after initial presentation. In general, the 35
patients who were without evidence of disease at last fol-
low-up, had a mean follow-up of 16.3 years. These results
yield a raw 5-year survival of 74 % and a raw 10-year
survival of 32.9 %. This contrasts to a disease-free 5-year
survival of 41.1 % and a disease-free 10-year survival of
24.7 %. The group of forty-three patients who developed
recurrent disease had a significantly worse outcome (79 %
died with disease, mean: 6.6 years; p \ 0.0001) whereas
those who did not develop recurrence had significantly
fewer deaths from disease (16.7 % died with disease;
mean: 5.9 years).
Most patients presented with low stage disease (stage I
or II; n = 42), while 15 patients presented with stage III
tumors and 29 patients presented with stage IV disease
(Table 6). Overall, as the stage of disease increased, there
was a statistically significant decrease in overall survival
and a greater number of patients died from or with disease
(Table 6): stage I, 48.6 % (mean 8.3 years); stage II, 60 %
(mean 3.8 years); stage III, 60 % (mean 3.6 years); and
stage IV, 55.1 % (mean 6.4 years).
As the grade of tumor increased, more patients were
likely to die from disease with shorter survival times: Grade
1: 50 % (7.8 years); Grade 2: 57 % (7.5 years); Grade 3:
52 % (3.8 years). Overall, the average follow-up decreased
as the grade increased: Grade 1: 12.5 years; Grade 2:
11.3 years; Grade 3: 7.5 years. However, this trend did not
quite reach statistical significance (p = 0.089).
A number of specific clinical and histologic features were
evaluated for prognostic significance (Table 6). Patients who
had tumors which developed recurrences (p \ 0.0001), with
perineural invasion (p \ 0.0001), bone invasion
(p = 0.0005), lymphovascular invasion (p = 0.0058),
involved a mixed anatomic site (p = 0.004), arranged in a
solid pattern (p = 0.006), or with a high stage at presentation
(p = 0.013) were each more likely to experience a worse
clinical outcome (Fig. 9).
Discussion
Etiology/Embryogenesis
It is believed that STACC arises from the mucoserous
glands of the upper aerodigestive tract, although the surface
epithelium appeared to be involved in 14 % of cases in this
study. While the surface is involved, it does not necessarily
imply that the tumor is arising from the surface epithelium
[5].
Most recently, it has been well shown that many ACCs,
including those outside of the major salivary glands, have a
recurrent translation, t(6;9), that juxtaopposes the MYB and
NFIB genes [139]. By in situ hybridization, we showed that
62 % of the tumors tested showed a broken MYB gene by
FISH. This is within the expected results for ACCs of any
site. Some authors have described rare STACCs possibly
arising secondary to infection by high-risk HPV, [140, 141]
although none of our cases tested harbored the virus.
Clinical Information
In our series as well as the patients reported in the litera-
ture, STACC are equally common in men and women. This
is similar to salivary gland ACC, although some report a
slight female predominance [142]. In general, the mean age
for STACC (54.5 years in our series and 49.2 for the lit-
erature) is younger than salivary gland ACC. Due to the
anatomic location within the sinonasal tract, tumors are
able to silently permeate the air-filled spaces, reaching a
considerable size before symptoms bring the patient to
clinical attention. The presenting symptoms are generally
non-specific, mimicking sinusitis or an obstructive lesion,
and were present for about 2 years before patients sought
clinical attention. This delay in diagnosis contributed to a
mean tumor size of about 3.7 cm [6, 86, 106]. The tumors
are large for this anatomic site, but it is probably related to
slow growth producing symptoms only after the tumors
have reached a considerable size. In contrast to salivary
gland ACC, pain or other neurological symptoms were not
commonly seen in STACC (12.8 %). Most of the tumors
involved multiple locations (52 %), although the nasal
cavity alone (29 %) was a common finding. Tumor
involvement of multiple sites correlated with a worse
patient outcome (p \ 0.0001) [7, 86]. This is also probably
correlated to the majority of patients showing higher stage
(III and IV) disease at presentation, involving sensitive
























Fig. 8 Overall actuarial survival of sinonasal tract adenoid cystic
carcinoma
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Table 6 Patient outcome based on various parameters (average years of follow-up)
All patients A, NED D, NED A, D D, D Statistical
significance
All patients with follow-up (mean) 86 (19.4) 19 (18.9) 16 (13.3) 5 (5.4) 46 (6.4) n/a
Follow-up range (years) 0.4 to 37.5 3.7 to 37.5 0.7 to 31.2 1.5 to 12.3 0.4 to 17.0 n/a
Sex
Males 41 (9.8) 8 (16.9) 10 (12.1) 2 (8.3) 21 (6.1) p = 0.687
Females 45 (10.9) 11 (20.3) 6 (15.2) 3 (3.6) 25 (6.7)
Age
\60 years 47 (12.2) 12 (22.1) 5 (18.1) 4 (5.8) 26 (7.5) p = 0.470
C60 years 39 (8.2) 7 (13.3) 11 (11.1) 1 (4.8) 20 (13.3)
Size
\4.0 cm 50 (10.6) 10 (20.0) 11 (12.3) 2 (5.5) 27 (6.8) p = 0.751
C4.0 cm 36 (10.1) 9 (17.6) 5 (15.3) 3 (5.4) 19 (5.9)
Lymphovascular invasion
Present 33 (6.6) 3 (6.4) 3 (13.0) 3 (4.2) 24 (6.1) p = 0.0058
Absent 53 (12.8) 16 (21.2) 13 (13.3) 2 (7.3) 22 (6.8)
Neural invasion
Present 47 (6.7) 6 (7.3) 2 (15.9) 4 (6.2) 35 (6.1) p < 0.0001
Absent 39 (14.9) 13 (24.3) 14 (12.9) 1 (2.4) 11 (7.5)
Bone invasion
Present 66 (8.8) 11 (16.7) 7 (14.8) 5 (5.5) 43 (6.2) p = 0.0005
Absent 20 (15.7) 8 (21.9) 9 (12.1) n/a 3 (9.9)
Necrosis
Present 16 (4.8) 4 (6.1) 1 (13.3) 2 (5.5) 9 (3.1) p = 0.806
Absent 70 (11.7) 15 (22.3) 15 (13.3) 3 (5.4) 37 (7.2)
Atypical mitoses
Present 11 (6.2) 2 (13.5) 1 (4.9) 1 (4.3) 7 (4.6) p = 0.473
Absent 75 (11.0) 17 (19.5) 15 (13.8) 4 (5.8) 39 (6.8)
Histologic type
Cribriform ([70 %) 33 (11.9) 6 (24.4) 10 (11.6) 1 (12.3) 16 (7.4) p = 0.101
Tubular ([70 %) 16 (11.1) 7 (13.1) 2 (9.4) n/a 7 (9.7)
Solid ([70 %) 9 (4.4) 1 (5.0) n/a 1 (2.4) 7 (4.5) p = 0.006
Grade p = 0.089
1 22 (12.5) 8 (17.6) 3 (16.1) n/a 11 (7.8)
2 37 (11.3) 6 (28.5) 8 (9.5) 2 (6.9) 21 (7.5)
3 27 (7.5) 5 (9.4) 5 (17.6) 3 (4.5) 14 (3.8)
Recurrence
With recurrence 52 (8.2) 2 (19.3) 5 (19.3) 4 (6.4) 41 (6.5) p < 0.0001
Without recurrences 34 (13.7) 17 (18.5) 11 (10.5) 1 (1.5) 5 (5.92)
Anatomic site
Maxillary sinus alone 4 (5.8) n/a n/a n/a 4 (5.8) p = 0.527
Nasal cavity alone 25 (15.9) 8 (24.4) 8 (14.5) n/a 9 (9.7) p = 0.004
Nasopharynx alone 13 (8.9) 3 (14.9) 2 (7.7) n/a 8 (7.0) p = 0.527
Mixed anatomic sites 44 (8.1) 8 (14.9) 6 (13.5) 5 (5.5) 25 (5.2) p < 0.000
Skull base involvement 26 (6.5) n/a 3 (14.4) 2 (4.6) 21 (5.5) p = 0.005
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Again, the higher stage disease was associated with a worse
outcome (p = 0.013) [6, 7, 24, 86, 106].
Pathology
STACC is characterized by a variety of histologic growth
patterns, all of which may be exhibited in a single tumor
mass. The three classic histologic patterns of ACC of sali-
vary glands (cribriform, tubular and solid) were seen in
STACC, and when these patterns predominated the diag-
nosis was very straightforward. We perceived two more
distinct and unique patterns seen in STACC lesions: anas-
tomosing cords and dilated spaces. Anastomosing cords are
characterized by parallel rows of tumor cells which at low
power give the appearance of creating pseudocysts.
Although the dilated spaces of the cribriform pattern seen in
oral cavity ACC may be variable in size, they still are rela-
tively small, producing a ‘‘Swiss cheese’’ appearance. In
STACC the cribriform pattern still resembles ‘‘Swiss
cheese’’ in areas; however, these spaces may be considerably
larger and appear dilated or less structured (flaccid) in other
areas of the lesion. These large dilated spaces may be filled
with glycosaminoglycan material, reduplicated basement
membrane material, or may appear to be empty. The tumor
cells in all patterns may be surrounded by a hyalinized
material or reduplicated basement membrane. These par-
ticular histologic patterns were not seen with sufficient fre-
quency, however, to suggest a difference in outcome.
However, the solid histologic pattern ([70 % solid growth)
was associated with a worse outcome (p = 0.006). This cut-
off is higher than 30 % used by others [6]. However, tumors
in the sinonasal tract are fragmented and often in multiple
parts, making a calculation of tumor ‘‘volume’’ more diffi-
cult. Further, while higher tumor grade was associated with
an overall shorter survival (Grade 1: 12.5 years vs. Grade 3:
7.5 years), this difference did not reach statistical
significance (p = 0.089), a finding similar to other authors
[84]. Interestingly, many of the parameters (necrosis, bone
invasion, perineural invasion, dominant pattern) when sep-
arately evaluated were significant (see below) while others
are not significant (mitoses, atypical mitoses, pleomor-
phism) or not valid (circumscription) in this anatomic site.
A highly characteristic feature of salivary gland ACC is
the tendency to show perineural invasion [6, 142]; however,
nerve symptoms were uncommon in STACC (12.8 %).
Perineural invasion was not a constant feature in STACC,
with perineural or intraneural involvement seen in 54.7 %
of cases, within the range of other reported series (40–91 %)
[6, 84]. Neural invasion did not correlate to stage, bone
invasion or lymphovascular invasion. The diameter of nerve
involved, whether intraneural or perineural, and whether the
nerves involved are within the tumor or distant from the
tumor did not seem to alter the outcome. Therefore, any
neural invasion is significant, contributing to a worse patient
outcome (p \ 0.0001) [6, 35, 38, 143]. It seems that nerve
invasion is not related to local invasion or proliferation, and
is an independent factor, possibly related to laminin-5
expression [144] or brain-derived neurotrophic factor [60].
Perineural invasion is highly correlated to both local
recurrence and poor outcomes (p = 0.0001), and it is well
documented that STACC have the highest local recurrence
rates of all head and neck sites of ACC [6, 98, 128].
By extension, the presence of both lymphovascular
invasion (p = 0.0058) and bone invasion (p = 0.0005) are
also statistically significantly correlated to recurrence and a
poor patient outcome, similar to other reports [6]. Lympho-
vascular invasion was seen in about 38 % of cases, with the
presence of metastatic disease in distant sites (lung, liver, and
bone) a common finding. The erosion of bone by the tumor
and expansion into adjacent structures (such as brain stem,
skull base, optic chiasm) is probably why this factor is also so
closely correlated to recurrence and long term outcome.
Table 6 continued
All patients A, NED D, NED A, D D, D Statistical
significance
Stage
I 37 (13.2) 9 (23.0) 10 (13.1) n/a 18 (8.3) p = 0.084
II 5 (8.8) 2 (16.4) n/a n/a 3 (3.8) p = 0.856
III 15 (8.5) 2 (19.3) 4 (13.9) n/a 9 (3.6) p = 0.878
IV 29 (8.1) 6 (13.4) 2 (12.9) 5 (5.5) 16 (6.4) p = 0.013
Treatment
Surgery only 46 (12.2) 10 (24.9) 9 (14.1) n/a 27 (6.9) p = 0.093
Radiation only 4 (4.1) n/a 2 (4.1) 1 (1.5) 1 (6.7) p = 0.277
Combination therapy 36 (8.8) 9 (12.2) 5 (15.4) 4 (6.4) 18 (5.7) p = 0.545
Bold values are statistically significant (p \ 0.05)
A, NED alive, no evidence of disease; D, NED Dead, no evidence of disease; A WD alive, with disease either local or metastatic; D, WD dead, with disease
either local or metastatic; n/a not applicable
Head and Neck Pathol (2014) 8:88–109 101
123
Profound pleomorphism, necrosis, and mitoses did
not independently predict a worse outcome. The more
rapidly dividing the tumor is, the more likely there is to
be apoptosis and necrosis. Therefore, it is logical these
two factors are related to one another. Atypical mitoses
are not common, with only 12.8 % of cases showing
atypical mitoses. Further, necrosis is not a common
finding in STACC. There is often surface erosion and
Fig. 9 Kaplan-Meier plots
based on various statistically
significant clinical and
histologic parameters. The
overall survival of sinonasal
tract adenoid cystic carcinoma




site) of the tumor, histologic
type, stage and tumor grade
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ulceration, but true tumor necrosis is uncommon
(18.6 %).
Immunohistochemical Studies
On a whole, immunohistochemistry was not required to
accurately diagnose STACC. The immunohistochemical
profile of STACC reveals the presence of two cell popu-
lations: epithelial and myoepithelial cells. Keratin and
CK5/6 identify the epithelial component, while smooth
muscle actin, S100 protein, calponin, smooth muscle
myosin heavy chain, and/or p63 identify the basal and
myoepithelial cells. CD117 tended to highlight the tubular
areas. Although a variety of immunohistochemical stains
for both cell types and multiple tumor proliferation markers
were performed in our study, they tended not to be specific
for STACC (Table 4). The variability in cellular immu-
noreactivity limits the effectiveness of immunohisto-
chemical panels for definitive diagnosis. However, GFAP
is generally negative, and CK20 is always negative. p16
overexpression was seen in all of our cases (luminal
nuclear and cytoplasmic reaction; stronger cytoplasmic
reaction than in those cases that had associated pleomor-
phic adenoma), but does not necessarily imply biologically
integrated HPV as a potential etiology, as it does with
oropharyngeal carcinoma [12]. None of the cases tested
contained high-risk HPV (which includes 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, and 66) by in situ hybridization,
different from a recent series reporting the presence of
HPV 33 specifically [141].
Ki-67 ranged from non-reactive up to 22 %. Using a
cutoff of 5 % or higher, there was no statistically signifi-
cant difference in outcome for those with a high prolifer-
ation index versus those with a low proliferation index:
mean 8.2 versus 10.5 years, respectively; and 64.3 versus
53.6 % dead of disease, respectively. This is different from
others who have reported a statistically significant differ-
ence [76, 77, 105]. However, an increased ki-67 index is
noted in pleomorphic adenoma that undergo malignant
transformation to ACC ex-pleomorphic adenoma [105,
145, 146].
Differential Diagnosis
STACC may morphologically masquerade as a variety of
benign and malignant neoplasms. In this series, 54.6 % of
cases were misclassified at the time of contribution. In
general, the differential diagnosis of STACC includes ba-
saloid squamous cell carcinoma (BSCC), olfactory neuro-
blastoma, small cell neuroendocrine carcinoma,
and epitheial-myoepthelial carcinoma, with other tumors
much less frequently observed. The short term biologic
behavior of ACC is much less aggressive than that of
BSCC with raw 5 year survival rates of about 75 %.
Regional lymph node metastasis is infrequent at presenta-
tion in STACC and distant metastasis occurs late in the
disease process. Histologically, ACC and BSCC may
exhibit similar growth patterns, since both can show
reduplicated basement membrane material and intercellular
mucohyaline material. Squamous cell differentiation is
lacking in ACC and the cells tend to be smaller and more
uniform, with angulated nuclei. Immunohistochemical
stains may assist in differentiating ACC from BSCC, but
there is considerable overlap so as to make them margin-
ally useful [147]. Olfactory neuroblastoma (ONB) is a
malignant neoplasm thought to arise from the olfactory
membrane of the sinonasal tract in the ethmoid sinus
(cribriform plate). High grade ONB may present diagnostic
difficulties with solid variant STACC. However, high
grade ONB grows in a lobular pattern, made up of pleo-
morphic cells with enlarged, hyperchromatic nuclei, vari-
able nucleoli, increased mitotic activity and necrosis
(confluent areas or individual cell). True neural rosettes
(Flexner-Wintersteiner type) may be present. Peripheral
nuclear palisading is seen in STACC and not in ONB.
Additionally, the immunohistochemical profile of ONB
shows little to absent cytokeratin, p63, and CD99 reactiv-
ity, while showing reactivity with chromogranin, synapto-
physin, and CD56, with S100 protein highlighting a
peripheral sustentacular cell pattern [148]. Sinonasal
undifferentiated carcinoma (SNUC) is a highly aggressive
malignant neoplasm of the nasal cavity and the paranasal
sinuses with absent histologic differentiation. The cellular
pleomorphism, hyperchromasia, scant cytoplasm, promi-
nent nucleoli, increased mitotic activity with atypical
forms, and usually well developed necrosis are different
from STACC. Further, the cribriform and tubular growth
patterns, presence of reduplicated basement membrane-like
material, and glycosaminoglycan material are absent in
SNUC. SNUC are consistently reactive with epithelial
markers, but CD117 and p63 are usually absent. Adeno-
squamous carcinoma (ASC) has an admixture of squamous
cell carcinoma and adenocarcinoma, features absent in
STACC. The surface epithelium with dysplasia, in situ
carcinoma or various proportions of squamous differenti-
ation in addition to peripheral nuclear palisading are
lacking in STACC [149]. Neuroendocrine carcinoma
(small cell or large cell types) tend to be more destructive
clinically, with cells showing a high nuclear to cytoplasmic
ratio, salt-and-pepper nuclear chromatin distribution, high
mitotic rate and tumor necrosis. There is no glandular or
cribriform pattern, although a rosette pattern could mimic a
cribriform appearance. The usually well developed dot-like
to punctate keratin immunoreactivity and strong, diffuse
synaptophysin, chromogranin, CD56, and NSE reactivity
should help to differentiation between STACC and
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neuroendocrine carcinoma. Importantly, CD117 is positive
in both tumors, while CK7 is negative in neuroendocrine
carcinomas and strongly positive in most STACC [29, 108,
150]. Epithelial-myoepithelial carcinoma usually has a
well defined biphasic appearance, with a dual population.
The myoepithelial cells often have a cleared cytoplasm.
This tumor type does not show a cribriform pattern. An
EMC-like pattern can be seen in adenoid cystic carcinoma.
Generally, sufficient sampling will help make this separa-
tion. Finally, it is important to consider that ACC may be
the malignant component of a carcinoma ex-pleomorphic
adenoma, as noted in nine of the current cases. However, it
is probably more important to thoroughly sample any SNT
pleomorphic adenoma to exclude an ACC, than to neces-
sarily try to identify a pleomorphic adenoma in a patient
presenting with ACC [23, 36, 105].
Treatment
Patients included in this report were managed at more than
80 different hospitals by a team of surgeons, oncologists,
and radiation therapists, among others. While the diagnosis
was rendered during the time of initial evaluation and
treatment (i.e., team knew the diagnosis during initial
treatment rather than finding out the correct diagnosis at the
time of a recurrence), inexperience with this uncommon
tumor will result in differences in surgical techniques
employed or follow-on chemoradiation protocols imple-
mented. It is for these reasons that specific recommenda-
tions about surgical technique, radiation protocols or doses
of chemotherapy regimens cannot be reliably postulated.
Patients were managed by surgery alone or surgery
combined with radiation therapy. It is nearly impossible to
achieve complete microscopical resection of STACC. Even
when surgical margins may be negative, skip lesions along
peripheral nerve trunks invalidate a negative margin. In this
study, as in many others [7, 52, 84, 86, 151], determination of
margins could not be reliably performed, but perhaps apro-
pos if the data is dearth. Perhaps, therefore, prudence would
suggest discontinuing or greatly reducing the submission of
multiple frozen section margins which unnecessarily pro-
long surgery, introduce frozen section artifacts, and provide
a false sense of security to the clinician and patient about the
success of extirpation. Knowing the morbidity of COM-
MANDO-type (COMbined MAxilectomy and Neck Dis-
section Operation) procedures in a disease where surgery
offers at best palliative care over the long term, the surgical
approach can be tempered to preserve functionality and a
better cosmetic outcome. It seems that no matter what
approach is employed, ultimately if followed long enough
the disease seems to recur. Further, with STACC showing
such a high proclivity for perineural invasion, extension into
the skull base is quite readily observed (30 %). Because the
tumor is slow growing and often has skip lesions, skull base
disease is often a late finding. As the skull base has a limited
blood supply, chemotherapy is not effective in this setting,
although radiation may be palliative [6, 52, 84, 86, 152].
When the skull base was affected, overall survival is much
shorter and more patients died with disease (p = 0.005): 26
patient had skull base involvement, surviving an average of
6.5 years and 80.8 % dead of disease versus patients without
skull base involvement having an average survival of
12.1 years and 41.7 % dead of disease. These findings are
similar to other reviews [6, 52, 84].
The majority of patients were managed by surgery alone
(53.4 %), but the remaining patients received combination
surgery and radiation therapy. Due to the prolonged clinical
course, radiation when combined with surgery does not
seem to significantly alter overall patient outcome
(p = 0.545), but may result in longer disease free survival.
One of the factors may be that the doses required for local
control in ACC ([70 Gy) often cannot be achieved in the
confines of the SNT without violating tolerance doses for the
adjacent organs or structures (ocular or visual toxic effects:
keratitis, photophobia, conjunctivitis, blindness; neurologic:
seizures, short-term memory loss, brain changes) [6, 55, 86,
92]. In this series, patients managed with surgery alone, had
an average follow-up of 12.2 years, with 58.7 % dead of
disease, while patients managed with combination therapy
had an average follow-up of 8.8 years, with 50 % dead of
disease. It is possible that tumors managed by surgery alone
were more localized and thus prone to a better prognosis
without any additional therapy. Since the disease is pro-
gressive and indolent, radiation is probably at best palliative,
delaying rather than preventing recurrences and providing
symptomatic relief while not significantly altering long term
outcome [7, 106]. Modifications of radiation regimens
(carbon ion boost and photo intensity-modulated radiation
therapy) may yield a better response, but requires more
careful evaluation [24, 86, 92]. While STACC is radiosen-
sitive, radiation alone is not considered curative [6]. Che-
motherapy does not seem to significantly impact outcome or
have a role in the management of STACC [69].
Prognosis
The overall 5-year and ten-year survival rate were 67.4 and
37.2 %, respectively, while the 5-and 10-year disease-free
survival rate were 45.3 and 36.0 %, respectively. These
findings are similar to major salivary gland survival which
is 76.9 and 61.6 % for 5- and 10 year overall survival rate,
and 44.2 and 23.0 % for 5- and 10-year disease free sur-
vival rates, respectively [7, 10, 11, 56, 59, 142]. Patients
may, therefore, live with local disease and/or metastatic
disease for extended periods of time, indicating the pro-
gressive and indolent nature of STACC, suggesting the
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10-year survival rate may be more important and further
underscoring the requirement for long-term clinical follow-
up and management. The overall mortality rate was 53 %
(mean 6.5 years). The overall survival for STACC of
67.4 % at 5-years is better than for age- and stage-matched
patients with sinonasal tract squamous cell carcinoma with
34–57 % alive at 5-years [11, 44, 45]. However, for
STACC, the prolonged nature of the disease suggests that
the histologic type and not just the stage must be taken into
consideration when planning management and follow-up
protocols.
The majority of patients in this series developed recur-
rence (60.5 %), within the range of other reported studies
(36–56 %) [6, 84]. It is important to note that recurrences
often developed soon after resection, but late recurrences
can be seen up to 14.8 years after initial presentation.
When distant metastases are present, lung, liver, and bone
are the most common sites, followed by brain, kidney, skin
and soft tissues [10, 57, 65, 76, 99, 121, 153].
The vast majority of patients present with local–regional
disease only (i.e., no lymph node or distant metastasis), a
finding confirmed in other studies [6, 84], although local
disease does not imply low stage disease. In fact, the
majority of patients present with high stage disease (stage
III and IV, 51.1 %), a finding associated with a worse
prognosis (p = 0.013). This finding also correlates with
mixed site location (i.e., more than one anatomic site
involved), along with involvement of the skull base
(p = 0.005). Patients with tumors of the nasal cavity alone
had a better prognosis than patients with tumors in the
nasopharynx alone or patients with mixed anatomic sites
(p \ 0.0001). Skull base involvement was also a statisti-
cally significant negative prognostic finding (p = 0.005)
[6]. With the known propensity of ACC to involve nerves,
perineural involvement in the sinonasal tract region corre-
lates with more advanced tumors and higher stage disease,
with the attendant proximity to vital structures, limiting the
ability to cure the patient [99]. Further, only 38.4 % of
patients developed metastatic disease. This may be due in
part to the periostium and bone acting as a barrier that is not
seen in major salivary gland primaries, and the relatively
sparse lymphatics within the bones of the sinonasal tract in
comparison to major salivary gland sites [100].
Neural, bone, and lymphovascular invasion were all
associated with a statistically significant difference in
patient outcome (p \ 0.0001, p = 0.0005, p = 0.0058,
respectively). Poor prognosis was also associated with a
mixed anatomic location (p \ 0.0001), a high stage at
presentation (stage IV, p \ 0.013), skull base involvement
(p = 0.005), recurrence (p \ 0.0001), and a predominantly
([70 %) solid histology (p = 0.006). Although with vari-
able results, these findings are supported by others who
have studied individual factors [45].
Conclusion
In conclusion, STACC, while rare, are distinct mucosal
tumors that represent the most common adenocarcinoma of
the sinonasal tract. The tumors display a variety of histologic
patterns, including: cribriform, tubular, solid, anastomosing
cords, and dilated spaces. All of these patterns may be seen in
an individual tumor. The diagnosis is substantially made on
an H&E stained slide, with immunohistochemistry occa-
sionally helpful in separation from tumors in the differential
diagnosis. In general, the prognosis of STACC is better than
other malignancies of the sinonasal tract. Poor prognosis is
statistically significantly associated with high tumor stage
(p = 0.013), skull base involvement (p = 0.005), lympho-
vascular invasion (p = 0.0058), solid histology
(p = 0.006), bone invasion (p = 0.0005), perineural inva-
sion (p \ 0.0001), a mixed anatomic site (p \ 0.0001), and
tumor recurrence (p \ 0.0001).
Acknowledgments The opinions or assertions contained herein are
the private views of the authors and are not to be construed as official
or as reflecting the views of Southern California Permanente Medical
Group. A special thanks to Ms. Hannah Herrera for her research
assistance.
References
1. Eveson JW. Salivary gland-type carcinomas. In: Barnes L, Eve-
son JW, Reichart P, Sidransky D, editors. Pathology and genetics:
head and neck tumours. Lyon: IARC Press; 2005. p. 24–5.
2. Franchi A, Santucci M, Wenig BM. Adenocarcinoma. In:
Barnes EL, Eveson JW, Reichart P, Sidransky D, editors.
Pathology and genetics head and neck tumours. Lyon: IARC
Press; 2005. p. 20–3.
3. Kleinsasser O, Schroeder HG. Adenocarcinomas of the inner
nose after exposure to wood dust. Morphological findings and
relationships between histopathology and clinical behavior in 79
cases. Arch Otorhinolaryngol. 1988;245:1–15.
4. Barnes L. Intestinal-type adenocarcinoma of the nasal cavity and
paranasal sinuses. Am J Surg Pathol. 1986;10:192–202.
5. Gnepp DR, Heffner DK. Mucosal origin of sinonasal tract
adenomatous neoplasms. Mod Pathol. 1989;2:365–71.
6. Lupinetti AD, Roberts DB, Williams MD, Kupferman ME,
Rosenthal DI, Demonte F, et al. Sinonasal adenoid cystic car-
cinoma: the M. D. Anderson Cancer Center experience. Cancer.
2007;110:2726–31.
7. Rhee CS, Won TB, Lee CH, Min YG, Sung MW, Kim KH, et al.
Adenoid cystic carcinoma of the sinonasal tract: treatment
results. Laryngoscope. 2006;116:982–6.
8. Ang KK, Jiang GL, Frankenthaler RA, Kaanders JH, Garden
AS, Delclos L, et al. Carcinomas of the nasal cavity. Radiother
Oncol. 1992;24:163–8.
9. Benazzou S, Arkha Y, Boulaadas M, Derraz S, Essakali L,
Kzadri M. Nasal adenoid cystic carcinoma with intracranial
extension. J Craniofac Surg. 2006;17:1026–9.
10. Bhattacharyya N. Factors predicting survival for cancer of the
ethmoid sinus. Am J Rhinol. 2002;16:281–6.
11. Bhattacharyya N. Survival and staging characteristics for non-
squamous cell malignancies of the maxillary sinus. Arch Oto-
laryngol Head Neck Surg. 2003;129:334–7.
Head and Neck Pathol (2014) 8:88–109 105
123
12. Boland JM, McPhail ED, Garcia JJ, Lewis JE, Schembri-
Wismayer DJ. Detection of human papilloma virus and p16
expression in high-grade adenoid cystic carcinoma of the head
and neck. Mod Pathol. 2012;25(4):529–36.
13. Bridger MW, Beale FA, Bryce DP. Carcinom of the paranasal
sinuses–a review of 158 cases. J Otolaryngol. 1978;7:379–88.
14. Buffoli A, Olivetti L, Micheletti E, Facchetti F, Moretti R.
Degree of malignancy of maxillary sinus cylindromas in relation
to histologic characteristics. Tumori. 1982;68:127–31.
15. Cantu G, Solero CL, Mariani L, Salvatori P, Mattavelli F, Pizzi
N, et al. Anterior craniofacial resection for malignant ethmoid
tumors–a series of 91 patients. Head Neck. 1999;21:185–91.
16. Cantu G, Bimbi G, Miceli R, Mariani L, Colombo S, Riccio S,
et al. Lymph node metastases in malignant tumors of the para-
nasal sinuses: prognostic value and treatment. Arch Otolaryngol
Head Neck Surg. 2008;134:170–7.
17. Carinci F, Curioni C, Padula E, Calearo C. Cancer of the nasal
cavity and paranasal sinuses: a new staging system. Int J Oral
Maxillofac Surg. 1996;25:34–9.
18. Carrau RL, Petruzzelli G, Cass SP. Adenoid cystic carcinoma of
the nasopharynx. Otolaryngol Head Neck Surg. 1995;112:501–2.
19. Caruso VG, Roncace EA, Brennan MT. Cylindroma of the
sphenoid sinus. A study of two cases. Trans Pa Acad Ophthal-
mol Otolaryngol. 1973;26:32–5.
20. Chen AM, Daly ME, Bucci MK, Xia P, Akazawa C, Quivey JM,
et al. Carcinomas of the paranasal sinuses and nasal cavity
treated with radiotherapy at a single institution over five dec-
ades: are we making improvement? Int J Radiat Oncol Biol
Phys. 2007;69:141–7.
21. Chen AY, Stewart MG. Pathologic quiz case 1. Adenoid cystic
carcinoma (ACC) of the ethmoid sinus. Arch Otolaryngol Head
Neck Surg. 1995;121:1320–3.
22. Chilla R, Schroth R, Eysholdt U, Droese M. Adenoid cystic
carcinoma of the head and neck. Controllable and uncontrollable
factors in treatment and prognosis. ORL J Otorhinolaryngol
Relat Spec. 1980;42:346–67.
23. Cimino-Mathews A, Lin BM, Chang SS, Boahene KD, Bishop
JA. Carcinoma ex pleomorphic adenoma of the nasal cavity.
Head Neck Pathol. 2011;5:405–9.
24. Combs SE, Konkel S, Schulz-Ertner D, Munter MW, Debus J,
Huber PE, et al. Intensity modulated radiotherapy (IMRT) in
patients with carcinomas of the paranasal sinuses: clinical ben-
efit for complex shaped target volumes. Radiat Oncol. 2006;
1:23.
25. Daly ME, Chen AM, Bucci MK, El-Sayed I, Xia P, Kaplan MJ,
et al. Intensity-modulated radiation therapy for malignancies of
the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol
Phys. 2007;67:151–7.
26. David SS. Adenoid cystic carcinoma of the maxillary sinus.
J Indian Med Assoc. 1976;66:15–7.
27. Deb T, Thingbaijam S, Devi HP, Singh MM, Singh TH, Sanasam
JC. Sinonasal and nasopharyngeal adenoidcystic carcinoma:
report of four cases. J Indian Med Assoc. 2004;102:104.
28. Delbouck C, Roper N, Aubert C, Souchay C, Choufani G,
Hassid S. Unusual presentation of adenoid cystic carcinoma of
the maxillary antrum. B-ENT. 2009;5:265–8.
29. Demonte F, Ginsberg LE, Clayman GL. Primary malignant
tumors of the sphenoidal sinus. Neurosurgery. 2000;46:1084–91.
30. Dickhoff P, Wallace CJ, MacRae ME, Campbell WN. Adenoid
cystic carcinoma: an unusual sellar mass. Can Assoc Radiol J.
1993;44:393–5.
31. Dolan EJ, Schwartz ML, Lewis AJ, Kassel EE, Cooper PW.
Adenoid cystic carcinoma: an unusual neurosurgical entity. Can
J Neurol Sci. 1985;12:65–8.
32. Douglas JG, Laramore GE, ustin-Seymour M, Koh WJ, Lindsley
KL, Cho P, et al. Neutron radiotherapy for adenoid cystic
carcinoma of minor salivary glands. Int J Radiat Oncol Biol
Phys. 1996;36:87–93.
33. Ellis ER, Million RR, Mendenhall WM, Parsons JT, Cassisi NJ.
The use of radiation therapy in the management of minor salivary
gland tumors. Int J Radiat Oncol Biol Phys. 1988;15:613–7.
34. Ferguson MJ, Dewar JA. Locally recurrent adenoid cystic car-
cinoma of the left antrum: response to epirubicin, cisplatin and
5-fluorouracil. Clin Oncol (R Coll Radiol). 2001;13:236–7.
35. Fordice J, Kershaw C, El Naggar A, Goepfert H. Adenoid cystic
carcinoma of the head and neck: predictors of morbidity and
mortality. Arch Otolaryngol Head Neck Surg. 1999;125:149–52.
36. Freeman SR, Sloan P. Carcinoma ex-pleomorphic adenoma of
the nasal septum with adenoid cystic and squamous carcino-
matous differentiation. Rhinology. 2003;41:118–21.
37. Fukuda S, Sakai N, Kamata SE, Nameki H, Kishimoto S, Nis-
hikawa N et al. Surgical results of skull base surgery for the
treatment of head and neck malignancies involving skull base:
multi-institutional studies on 143 cases in Japan. Auris Nasus
Larynx. 2001;28(Suppl):S71–5.
38. Gil Z, Carlson DL, Gupta A, Lee N, Hoppe B, Shah JP, et al.
Patterns and incidence of neural invasion in patients with can-
cers of the paranasal sinuses. Arch Otolaryngol Head Neck Surg.
2009;135:173–9.
39. Goepfert H, Luna MA, Lindberg RD, White AK. Malignant
salivary gland tumors of the paranasal sinuses and nasal cavity.
Arch Otolaryngol. 1983;109:662–8.
40. Gotte K, Ganssmann S, Affolter A, Schafer C, Riedel F, Arens N,
et al. Dual FISH analysis of benign and malignant tumors of the
salivary glands and paranasal sinuses. Oncol Rep. 2005;14:1103–7.
41. Greenbaum EI, Gunn W, Rappaport I, O’Loughlin BJ. Cylin-
droma of the maxillary antrum. A case presentation and review
of the literature. Radiol Clin Biol. 1970;39:419–26.
42. Gullane PJ, Conley J. Carcinoma of the maxillary sinus. A
correlation of the clinical course with orbital involvement,
pterygoid erosion or pterygopalatine invasion and cervical
metastases. J Otolaryngol. 1983;12:141–5.
43. Hara HJ. Cancer of the nasopharynx. Review of the literature.
Report of 72 cases. Laryngoscope. 1969;79:1315–29.
44. Haraguchi H, Ebihara S, Saikawa M, Mashima K, Haneda T,
Hirano K. Malignant tumors of the nasal cavity: review of a
60-case series. Jpn J Clin Oncol. 1995;25:188–94.
45. Harbo G, Grau C, Bundgaard T, Overgaard M, Elbrond O,
Sogaard H, et al. Cancer of the nasal cavity and paranasal
sinuses. A clinico-pathological study of 277 patients. Acta
Oncol. 1997;36:45–50.
46. Hawkins RB, Wynstra JH, Pilepich MV, Fields JN. Carcinoma
of the nasal cavity–results of primary and adjuvant radiotherapy.
Int J Radiat Oncol Biol Phys. 1988;15:1129–33.
47. Higashi K, Jin Y, Johansson M, Heim S, Mandahl N, Biorklund
A, et al. Rearrangement of 9p13 as the primary chromosomal
aberration in adenoid cystic carcinoma of the respiratory tract.
Genes Chromosomes Cancer. 1991;3:21–3.
48. Howard DJ, Lund VJ. Reflections on the management of ade-
noid cystic carcinoma of the nasal cavity and paranasal sinuses.
Otolaryngol Head Neck Surg. 1985;93:338–41.
49. Howard DJ, Lund VJ. The role of midfacial degloving in
modern rhinological practice. J Laryngol Otol. 1999;113:885–7.
50. Huang M, Ma D, Sun K, Yu G, Guo C, Gao F. Factors influ-
encing survival rate in adenoid cystic carcinoma of the salivary
glands. Int J Oral Maxillofac Surg. 1997;26:435–9.
51. Iannetti G, Valentini V, Rinna C, Ventucci E, Marianetti TM.
Ethmoido-orbital tumors: our experience. J Craniofac Surg.
2005;16:1085–91.
52. Issing PR, Hemmanouil I, Stover T, Kempf HG, Wilkens L,
Heermann R, et al. Adenoid cystic carcinoma of the skull base.
Skull Base Surg. 1999;9:271–5.
106 Head and Neck Pathol (2014) 8:88–109
123
53. Jan GM, Wani MA, Goswami KC. Adenoid cystic carcinoma
(ACC) of left sphenoidal sinus (case report). Indian J Pathol
Microbiol. 1989;32:142–5.
54. Jansen EP, Keus RB, Hilgers FJ, Haas RL, Tan IB, Bartelink H.
Does the combination of radiotherapy and debulking surgery
favor survival in paranasal sinus carcinoma? Int J Radiat Oncol
Biol Phys. 2000;48:27–35.
55. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman
RW, Villaret DB. Malignant tumors of the nasal cavity and
paranasal sinuses. Head Neck. 2002;24:821–9.
56. Kim GE, Park HC, Keum KC, Lee CG, Suh CO, Hur WJ, et al.
Adenoid cystic carcinoma of the maxillary antrum. Am J Oto-
laryngol. 1999;20:77–84.
57. King DT, Cihak RW, Luther PK, Gurevitch AW, Hirose FM.
Malignant neoplasms of the paranasal sinuses involving the
skin. Arch Dermatol. 1978;114:1681–3.
58. Kokemuller H, Eckardt A, Brachvogel P, Hausamen JE. Ade-
noid cystic carcinoma of the major and minor salivary glands.
Retrospective analysis of 74 patients. Mund Kiefer Gesichtschir.
2003;7:94–101.
59. Konno A, Ishikawa K, Numata T, Nagata H, Terada N,
Okamoto Y. Analysis of factors affecting long-term treatment
results of adenoid cystic carcinoma of the nose and paranasal
sinuses. Acta Otolaryngol Suppl. 1998;537:67–74.
60. Kowalski PJ, Paulino AF. Perineural invasion in adenoid cystic
carcinoma: its causation/promotion by brain-derived neurotro-
phic factor. Hum Pathol. 2002;33:933–6.
61. Kraus DH, Roberts JK, Medendorp SV, Levine HL, Wood BG,
Tucker HM, et al. Nonsquamous cell malignancies of the par-
anasal sinuses. Ann Otol Rhinol Laryngol. 1990;99:5–11.
62. Kwon RO, Lyon DB, Floyd M, Girod DA. Sinonasal adenoid
cystic carcinoma presenting as an orbital mass. Ophthal Plast
Reconstr Surg. 2010;26:54–6.
63. Le QT, Birdwell S, Terris DJ, Gabalski EC, Varghese A, Fee W Jr,
et al. Postoperative irradiation of minor salivary gland malignan-
cies of the head and neck. Radiother Oncol. 1999;52:165–71.
64. Lee DJ, Smith RR, Spaziani JT, Rostock R, Holliday M, Moses H.
Adenoid cystic carcinoma of the nasopharynx. Case reports and
literature review. Ann Otol Rhinol Laryngol. 1985;94:269–72.
65. Lee WJ, Kapadia SB, Stack BC Jr. Sinonasal adenoid cystic
carcinoma with widespread symptomatic bony metastasis. Ear
Nose Throat J. 2004;83:271–3.
66. Lloyd S, Yu JB, Wilson LD, Decker RH. Determinants and
patterns of survival in adenoid cystic carcinoma of the head and
neck, including an analysis of adjuvant radiation therapy. Am J
Clin Oncol. 2011;34:76–81.
67. Loh KS, Barker E, Bruch G, O’Sullivan B, Brown DH, Gold-
stein DP, et al. Prognostic factors in malignancy of the minor
salivary glands. Head Neck. 2009;31:58–63.
68. Lopez-Gines C, Cerda-Nicolas M, Llombart-Bosch A. Cytoge-
netic findings in a new case of adenoid cystic carcinoma arising
in sphenoidal sinus. Cancer Genet Cytogenet. 1994;75:150–2.
69. Madison ML, Sorenson JM, Samant S, Robertson JH. The
treatment of advanced sinonasal malignancies with pre-opera-
tive intra-arterial cisplatin and concurrent radiation. J Neuroon-
col. 2005;72:67–75.
70. Mann W, Schuler-Voith C. Tumors of the paranasal sinuses and
the nose: a retrospective study in 136 patients. Rhinology.
1983;21:173–7.
71. McMillan MD, Anderson G. Maxillary adenoid cystic carci-
noma with annulate lamellae. Ultrastruct Pathol. 1994;18:493–8.
72. Miller CL, Offutt WN, Kielar RA. Adenoid cystic carcinoma of
the antrum and epiphora. Am J Ophthalmol. 1977;83:582–6.
73. Miller RH, Calcaterra TC. Adenoid cystic carcinoma of the
nose, paranasal sinuses, and palate. Arch Otolaryngol. 1980;
106:424–6.
74. Myers LL, Nussenbaum B, Bradford CR, Teknos TN, Esclam-
ado RM, Wolf GT. Paranasal sinus malignancies: an 18-year
single institution experience. Laryngoscope. 2002;112:1964–9.
75. Naficy S, Disher MJ, Esclamado RM. Adenoid cystic carcinoma
of the paranasal sinuses. Am J Rhinol. 1999;13:311–4.
76. Nagao T, Gaffey TA, Serizawa H, Sugano I, Ishida Y, Yamazaki
K, et al. Dedifferentiated adenoid cystic carcinoma: a clinico-
pathologic study of 6 cases. Mod Pathol. 2003;16:1265–72.
77. Nordgard S, Franzen G, Boysen M, Halvorsen TB. Ki-67 as a
prognostic marker in adenoid cystic carcinoma assessed with the
monoclonal antibody MIB1 in paraffin sections. Laryngoscope.
1997;107:531–6.
78. Oppenheim H, Landau GH, Dorman DW, Mojsejenko I, Sleadd
FB. Cylindroma involving the paranasal sinuses. Eye Ear Nose
Throat Mon. 1968;47:669–78.
79. Ozsaran Z, Yalman D, Baltalarli B, Anacak Y, Esassolak M,
Haydaroglu A. Radiotherapy in maxillary sinus carcinomas:
evaluation of 79 cases. Rhinology. 2003;41:44–8.
80. Panchal L, Vaideeswar P, Kathpal D, Madiwale CV, Prabhat
DP. Sino-nasal epithelial tumours: a pathological study of 69
cases. J Postgrad Med. 2005;51:30–5.
81. Parsons JT, Mendenhall WM, Mancuso AA, Cassisi NJ, Million
RR. Malignant tumors of the nasal cavity and ethmoid and
sphenoid sinuses. Int J Radiat Oncol Biol Phys. 1988;14:11–22.
82. Perez AJ, Goyal P. Adenoid cystic carcinoma of the nasal
cavity: a case report. Ear Nose Throat J. 2012;91:E22–4.
83. Perusse R. Adenoid cystic carcinoma of the maxillary sinus.
J Am Dent Assoc. 1997;128:1551–5.
84. Pitman KT, Prokopakis EP, Aydogan B, Segas J, Carrau RL,
Snyderman CH, et al. The role of skull base surgery for the
treatment of adenoid cystic carcinoma of the sinonasal tract.
Head Neck. 1999;21:402–7.
85. Poetker DM, Toohill RJ, Loehrl TA, Smith TL. Endoscopic
management of sinonasal tumors: a preliminary report. Am J
Rhinol. 2005;19:307–15.
86. Pommier P, Liebsch NJ, Deschler DG, Lin DT, McIntyre JF,
Barker FG, et al. Proton beam radiation therapy for skull base
adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg.
2006;132:1242–9.
87. Ramsden D, Sheridan BF, Newton NC, De Wilde FW. Adenoid
cystic carcinoma of the head and neck: a report of 30 cases. Aust
N Z J Surg. 1973;43:102–8.
88. Rudralingam M, Jones K, Woolford TJ. The unilateral opaque
maxillary sinus on computed tomography. Br J Oral Maxillofac
Surg. 2002;40:504–7.
89. Sadeghi A, Tran LM, Mark R, Sidrys J, Parker RG. Minor
salivary gland tumors of the head and neck: treatment strategies
and prognosis. Am J Clin Oncol. 1993;16:3–8.
90. Sato K, Ueda Y, Sakurai A, Ishikawa Y, Kaji S, Nojima T, et al.
Adenoid cystic carcinoma of the maxillary sinus with gradual
histologic transformation to high-grade adenocarcinoma: a
comparative report with dedifferentiated carcinoma. Virchows
Arch. 2006;448:204–8.
91. Schramm VL Jr, Imola MJ. Management of nasopharyngeal
salivary gland malignancy. Laryngoscope. 2001;111:1533–44.
92. Schulz-Ertner D, Didinger B, Nikoghosyan A, Jakel O, Zuna I,
Wannenmacher M, et al. Optimization of radiation therapy for
locally advanced adenoid cystic carcinomas with infiltration of
the skull base using photon intensity-modulated radiation ther-
apy (IMRT) and a carbon ion boost. Strahlenther Onkol.
2003;179:345–51.
93. Shotton JC, Schmid S, Fisch U. The infratemporal fossa
approach for adenoid cystic carcinoma of the skull base and
nasopharynx. Otolaryngol Clin North Am. 1991;24:1445–64.
94. Sivaji N, Basavaraj S, Stewart W, Dempster J. Adenoid cystic
carcinoma of the nasal septum. Rhinology. 2003;41:253–4.
Head and Neck Pathol (2014) 8:88–109 107
123
95. Sofferman RA, Heisse JW Jr. Adenoid cystic carcinoma of the
nasopharynx after previous adenoid irradiation. Laryngoscope.
1985;95:458–61.
96. Solares CA, Fakhri S, Batra PS, Lee J, Lanza DC. Transnasal
endoscopic resection of lesions of the clivus: a preliminary
report. Laryngoscope. 2005;115:1917–22.
97. Spiro RH, Koss LG, Hajdu SI, Strong EW. Tumors of minor
salivary origin. A clinicopathologic study of 492 cases. Cancer.
1973;31:117–29.
98. Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma:
factors influencing survival. Am J Surg. 1979;138:579–83.
99. Strick MJ, Kelly C, Soames JV, McLean NR. Malignant
tumours of the minor salivary glands–a 20 year review. Br J
Plast Surg. 2004;57:624–31.
100. Sung MW, Kim KH, Kim JW, Min YG, Seong WJ, Roh JL,
et al. Clinicopathologic predictors and impact of distant
metastasis from adenoid cystic carcinoma of the head and neck.
Arch Otolaryngol Head Neck Surg. 2003;129:1193–7.
101. Takagi D, Fukuda S, Furuta Y, Yagi K, Homma A, Nagahashi T
et al. Clinical study of adenoid cystic carcinoma of the head and
neck. Auris Nasus Larynx. 2001;28(Suppl):S99–102.
102. Takahashi T, Mitsuhashi N, Sakurai H, Takahashi M, Hirato J,
Niibe H. A case report of adenoid cystic carcinoma of the
nasopharynx with aggressive systemic bone metastases. Radiat
Med. 1995;13:301–3.
103. Taylor JS, Cooley HN, Hicks JJ. Cylindroma of the maxillary
antrum. Laryngoscope. 1965;75:1727–36.
104. Thorup C, Sebbesen L, Dano H, Leetmaa M, Andersen M,
Buchwald C, et al. Carcinoma of the nasal cavity and para-
nasal sinuses in Denmark 1995–2004. Acta Oncol. 2010;49:
389–94.
105. Toluie S, Thompson LD. Sinonasal tract adenoid cystic carci-
noma ex-pleomorphic adenoma: a clinicopathologic and
immunophenotypic study of 9 cases combined with a compre-
hensive review of the literature. Head Neck Pathol. 2012;6:
409–21.
106. Tran L, Sidrys J, Horton D, Sadeghi A, Parker RG. Malignant
salivary gland tumors of the paranasal sinuses and nasal cavity.
The UCLA experience. Am J Clin Oncol. 1989;12:387–92.
107. Tufano RP, Mokadam NA, Montone KT, Weinstein GS, Chalian
AA, Wolf PF, et al. Malignant tumors of the nose and paranasal
sinuses: hospital of the University of Pennsylvania experience
1990–1997. Am J Rhinol. 1999;13:117–23.
108. Vedrine PO, Thariat J, Merrot O, Percodani J, Dufour X, Cho-
ussy O, et al. Primary cancer of the sphenoid sinus–a GETTEC
study. Head Neck. 2009;31:388–97.
109. Veillon BJ, Raila FA, Fratkin JD, Russell WF. Magnetic resonance
imaging of massive intracranial invasion by an ethmoidal adenoid
cystic carcinoma (cylindroma). South Med J. 1996;89:321–3.
110. Wakisaka S, Nonaka A, Morita Y, Fukui M, Kinoshita K.
Adenoid cystic carcinoma with intracranial extension: report of
three cases. Neurosurgery. 1990;26:1060–5.
111. Wang CC, See LC, Hong JH, Tang SG. Nasopharyngeal adenoid
cystic carcinoma: five new cases and a literature review. J Oto-
laryngol. 1996;25:399–403.
112. Weber AL, Stanton AC. Malignant tumors of the paranasal
sinuses: radiologic, clinical, and histopathologic evaluation of
200 cases. Head Neck Surg. 1984;6:761–76.
113. Wiseman SM, Popat SR, Rigual NR, Hicks WL Jr, Orner JB,
Wein RO, et al. Adenoid cystic carcinoma of the paranasal
sinuses or nasal cavity: a 40-year review of 35 cases. Ear Nose
Throat J. 2002;81:510–7.
114. Wolff AP, Ossoff RH, Clemis JD. Four unusual neoplasms of
the nasopharynx. Otolaryngol Head Neck Surg. 1980;88:753–9.
115. Wolfowitz BL, Schmaman A. Unusual malignant tumours of the
maxillary sinuses. S Afr Med J. 1975;49:387–91.
116. Wolfowitz BL. Adenoid cystic carcinoma of the paranasal
sinuses. S Afr Med J. 1971;45:972–4.
117. Wright ED, Raza SN, Heathcote JG. Atypical diagnostic,
endoscopic, and pathologic findings in a case of adenoid cystic
carcinoma arising from the sphenoid sinus. J Otolaryngol.
2005;34:226–30.
118. Yin ZY, Wu XL, Hu YH, Gu XZ. Cylindroma of the naso-
pharynx: a chronic disease. Int J Radiat Oncol Biol Phys.
1986;12:25–30.
119. Zhang Q, Yang L, Yang AK, Guo ZM. Clinical study on 88
cases of adenoid cystic carcinoma in nasal cavity and paranasal
sinuses. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.
2009;44:311–4.
120. Kuo YL, Tu TY, Chang CF, Li WY, Chang SY, Shiao AS, et al.
Extra-major salivary gland pleomorphic adenoma of the head
and neck: a 10-year experience and review of the literature. Eur
Arch Otorhinolaryngol. 2011;268:1035–40.
121. Shukla NK, Hazarika S, Deo S, Kar M, Kumar S, Samaiya A,
et al. Salivary gland tumours: profile and management at a
tertiary cancer centre. J Indian Med Assoc. 2011;109:381–5.
122. Iyer NG, Kim L, Nixon IJ, Palmer F, Kraus D, Shaha AR, et al.
Factors predicting outcome in malignant minor salivary gland
tumors of the oropharynx. Arch Otolaryngol Head Neck Surg.
2010;136:1240–7.
123. Licitra L, Locati LD, Bossi P, Cantu G. Head and neck tumors
other than squamous cell carcinoma. Curr Opin Oncol.
2004;16:236–41.
124. Lewis JE, Olsen KD, Sebo TJ. Carcinoma ex pleomorphic adenoma:
pathologic analysis of 73 cases. Hum Pathol. 2001;32:596–604.
125. Nordkvist A, Roijer E, Bang G, Gustafsson H, Behrendt M, Ryd
W, et al. Expression and mutation patterns of p53 in benign and
malignant salivary gland tumors. Int J Oncol. 2000;16:477–83.
126. Gnepp DR. Malignant mixed tumors of the salivary glands: a
review. Pathol Annu. 1993;28(Pt 1):279–328.
127. Batsakis JG. Neoplasms of the minor and lesser major salivary
glands. Surg Gynecol Obstet. 1972;135:289–98.
128. Spiro RH, Huvos AG. Stage means more than grade in adenoid
cystic carcinoma. Am J Surg. 1992;164:623–8.
129. Batsakis JG, Rice DH, Solomon AR. The pathology of head and
neck tumors: squamous and mucous-gland carcinomas of the
nasal cavity, paranasal sinuses, and larynx, part 6. Head Neck
Surg. 1980;2:497–508.
130. Batsakis JG. Mucous gland tumors of the nose and paranasal
sinuses. Ann Otol Rhinol Laryngol. 1970;79:557–62.
131. Das S, Kirsch CF. Imaging of lumps and bumps in the nose: a
review of sinonasal tumours. Cancer Imaging. 2005;5:167–77.
132. Chang PC, Fischbein NJ, McCalmont TH, Kashani-Sabet M,
Zettersten EM, Liu AY, et al. Perineural spread of malignant
melanoma of the head and neck: clinical and imaging features.
AJNR Am J Neuroradiol. 2004;25:5–11.
133. Lloyd G, Lund VJ, Howard D, Savy L. Optimum imaging for
sinonasal malignancy. J Laryngol Otol. 2000;114:557–62.
134. Farman AG, George DI Jr, Clear RM. Computerized tomogra-
phy of combined carcinomas arising in pleomorphic adenoma.
Oral Surg Oral Med Oral Pathol. 1985;59:96–101.
135. Calearo C, Pastore A, Merlo R. Cancer of the facial mass. Acta
Otorhinolaryngol Ital. 1987;7(Suppl 14):1–27.
136. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2009.
137. Batsakis JG, Luna MA, El-Naggar A. Histopathologic grading
of salivary gland neoplasms: III. Adenoid cystic carcinomas.
Ann Otol Rhinol Laryngol. 1990;99:1007–9.
138. Szanto PA, Luna MA, Tortoledo ME, White RA. Histologic
grading of adenoid cystic carcinoma of the salivary glands.
Cancer. 1984;54:1062–9.
139. Moskaluk CA. Adenoid cystic carcinoma: clinical and molecu-
lar features. Head Neck Pathol. 2013;7:17–22.
108 Head and Neck Pathol (2014) 8:88–109
123
140. Boland JM, McPhail ED, Garcia JJ, Lewis JE, Schembri-
Wismayer DJ. Detection of human papilloma virus and p16
expression in high-grade adenoid cystic carcinoma of the head
and neck. Mod Pathol. 2012;25:529–36.
141. Bishop JA, Ogawa T, Stelow EB, Moskaluk CA, Koch WM, Pai
SI, et al. Human papillomavirus-related carcinoma with adenoid
cystic-like features: a peculiar variant of head and neck cancer
restricted to the sinonasal tract. Am J Surg Pathol. 2013;37:
836–44.
142. Ellis GL, Auclair PL. Tumors of the salivary glands, vol. 17. 3rd
Series ed. Washington: Armed Forces Institute of Pathology;
1995.
143. Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Hiner-
man RW, Villaret DB. Radiotherapy alone or combined with
surgery for adenoid cystic carcinoma of the head and neck. Head
Neck. 2004;26:154–62.
144. Anderson TD, Feldman M, Weber RS, Ziober AF, Ziober BL.
Tumor deposition of laminin-5 and the relationship with peri-
neural invasion. Laryngoscope. 2001;111:2140–3.
145. Katori H, Nozawa A, Tsukuda M. Increased expression of
cyclooxygenase-2 and Ki-67 are associated with malignant
transformation of pleomorphic adenoma. Auris Nasus Larynx.
2007;34:79–84.
146. Chimona TS, Koutsopoulos AV, Malliotakis P, Nikolidakis A,
Skoulakis C, Bizakis JG. Malignant mixed tumor of the nasal
cavity. Auris Nasus Larynx. 2006;33:63–6.
147. Wieneke JA, Thompson LD, Wenig BM. Basaloid squamous
cell carcinoma of the sinonasal tract. Cancer. 1999;85:841–54.
148. Thompson LD. Olfactory neuroblastoma. Head Neck Pathol.
2009;3:252–9.
149. Barnes L, Ferlito A, Altavilla G, MacMillan C, Rinaldo A,
Doglioni C. Basaloid squamous cell carcinoma of the head and
neck: clinicopathological features and differential diagnosis.
Ann Otol Rhinol Laryngol. 1996;105:75–82.
150. Thompson LD, Seethala RR, Muller S. Ectopic Sphenoid Sinus
Pituitary Adenoma (ESSPA) with Normal Anterior Pituitary
Gland: a Clinicopathologic and Immunophenotypic Study of 32
Cases with a Comprehensive Review of the English Literature.
Head Neck Pathol. 2012;6:75–100.
151. Perzin KH, Gullane P, Clairmont AC. Adenoid cystic carcino-
mas arising in salivary glands: a correlation of histologic fea-
tures and clinical course. Cancer. 1978;42:265–82.
152. Diaz EM, Jr., Kies MS. Chemotherapy for skull base cancers.
Otolaryngol Clin North Am 2001;34:1079–85, viii.
153. Vrionis FD, Kienstra MA, Rivera M, Padhya TA. Malignant tumors
of the anterior skull base. Cancer Control. 2004;11:144–51.
Head and Neck Pathol (2014) 8:88–109 109
123
